Zevra Therapeutics Management

Management Kriterienprüfungen 0/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Neil McFarlane

Geschäftsführender

US$3.4m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts4.6%
Amtszeit als Geschäftsführer1.1yrs
Eigentum des Geschäftsführersn/a
Durchschnittliche Amtszeit des Managements1.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder1.6yrs

Jüngste Management Updates

Recent updates

Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results

Nov 15
Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results

Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%

Aug 30
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%

Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors

Jul 12
Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors

Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically

Apr 07
Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates

Apr 04
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates

Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors

Apr 02
Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors

Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects

Dec 28
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects

Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts

Sep 05
Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts

This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year

Aug 20
This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable

Apr 17
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable

US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results

Mar 10
US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results

Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?

Mar 08
Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?

Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates

Nov 16
Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates

Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?

Nov 11
Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?

KemPharm posts Phase 1 data to support further studies for sleep disorder therapy

Sep 28

KemPharm wins Buy rating at Canaccord on CNS focus

Sep 15

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Neil McFarlane im Vergleich zu den Einnahmen von Zevra Therapeutics verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

-US$90m

Jun 30 2024n/an/a

-US$67m

Mar 31 2024n/an/a

-US$49m

Dec 31 2023US$3mUS$158k

-US$46m

Vergütung im Vergleich zum Markt: NeilDie Gesamtvergütung ($USD3.45M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD2.18M).

Entschädigung vs. Einkommen: Unzureichende Daten, um die Vergütung von Neil mit der Unternehmensleistung zu vergleichen.


Geschäftsführer

Neil McFarlane (51 yo)

1.1yrs

Amtszeit

US$3,445,231

Vergütung

Mr. Neil F. McFarlane serves as President & Chief Executive Officer at Zevra Therapeutics, Inc. since October 10, 2023 and serves as its Director since October 9, 2023. He served as Independent Director at...


Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Neil McFarlane
President1.1yrsUS$3.45mkeine Daten
Christal M. Mickle
Co-Founder & Chief Development Officerno dataUS$1.67m0.051%
$ 248.5k
R. Clifton
CFO, Secretary & Treasurer9.4yrsUS$2.26m0.035%
$ 168.6k
Joshua Schafer
Chief Commercial Officer & Executive VP of Business Development1.8yrsUS$1.82m0.0066%
$ 32.0k
Sven Guenther
Chief Scientific Officer1.8yrsUS$1.08m0.0051%
$ 25.0k
Nichol Ochsner
Vice President of Investor Relations & Corporate Communications2.3yrskeine Datenkeine Daten
Rahsaan Thompson
Chief Legal Officerless than a yearkeine Datenkeine Daten
Alison Peters
Chief People Officerless than a yearkeine Datenkeine Daten
Christopher Lauderback
Senior Vice President of Manufacturing1.8yrskeine Datenkeine Daten
Rene Braeckman
Senior Vice President of Clinical Development1.8yrskeine Datenkeine Daten
Daniel Gallo
Senior Vice President of Medical Affairs & Advocacy1.8yrskeine Datenkeine Daten
Adrian Quartel
Chief Medical Officerless than a yearkeine Datenkeine Daten

1.8yrs

Durchschnittliche Betriebszugehörigkeit

52yo

Durchschnittliches Alter

Erfahrenes Management: ZVRADas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.8 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.


Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Neil McFarlane
President1.1yrsUS$3.45mkeine Daten
Wendy Dixon
Independent Director1.6yrsUS$274.00k0%
$ 0
Douglas Calder
Independent Director1.6yrsUS$258.02k0%
$ 0
Tamara Favorito
Independent Chair3.3yrsUS$324.39k0.0014%
$ 6.6k
Donald Jasinski
Member of Scientific and Medical Advisory Boardno datakeine Datenkeine Daten
John Bode
Independent Director1.6yrsUS$264.31k0.056%
$ 273.9k
Corey Watton
Independent Director1.6yrsUS$260.67k0.0028%
$ 13.7k
Barney Bishop
Chairman of Scientific and Medical Advisory Board17.8yrskeine Datenkeine Daten
Robert Findling
Member of Scientific & Medical Advisory Boardno datakeine Datenkeine Daten
Jeffrey Gudin
Co-Chair of Physician Advisory Council11.1yrskeine Datenkeine Daten
Srinivas Nalamachu
Co-Chair of Physician Advisory Council11.1yrskeine Datenkeine Daten
Thomas Anderson
Independent Director1.3yrsUS$243.04k0.037%
$ 182.6k

1.6yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrener Vorstand: ZVRADie Vorstandsmitglieder gelten nicht als erfahren ( 1.6 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.